A 2023 cardiovascular outcomes trial (SELECT) confirmed semaglutide's safety in a broader population, showing no unexpected safety signals in over 17,600 participants with cardiovascular disease or risk factors

Works best for Adults with BMI 30+ who have struggled to lose weight through diet/exercise People with strong food cravings or "food noise" driving overeating Those with insulin resistance or prediabetes (semaglutide improves both) Patients willing to commit to ongoing treatment not a short-term fix People who pair medication with improved diet and activity habits Works less well or is not appropriate for People expecting results without any dietary changes it reduces appetite, but diet quality still matters Those who cannot tolerate GI side effects even at low doses People with personal/family history of certain thyroid conditions (contraindicated) Anyone expecting permanent results after stopping weight typically returns Patients without a plan for long-term access and cost management What happens when you stop taking it
Peptigo ships every batch with a Janoshik Analytical COA covering that full panel
Tired all the time, wasnt sleeping great
Overall, these MS-identified interactions suggest that the effect of GLP-1R PKA signalling at ERMCS might extend well beyond the MICOS complex into a more comprehensive programme of ER, mitochondria and lipid metabolic pathway regulation
Potential Research Applications: Sustained growth hormone release studies Muscle growth, recovery, and anti-aging research models Fat metabolism and body composition investigations Long-acting GHRH analog research For laboratory research only